UMB-136

UMB-136 is a bromodomain inhibitor. UMB-136 is a promising latency-reversing agent (LRA) for HIV-1 eradication. UMB-136 reactivates HIV-1 in multiple cell models. UMB-136 enhances HIV-1 transcription and increases viral production through the release of P-TEFb[1].

Product Specifications

CAS Number

[2109805-83-4]

UNSPSC

12352005

Hazard Statement

H302

Target

Epigenetic Reader Domain; HIV

Type

Reference compound

Related Pathways

Anti-infection; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/umb-136.html

Solubility

10 mM in DMSO

Smiles

COC1=CC(C2=C(ON=C2C)C)=CC=C1C3=C(N4C(C=NC=C4)=N3)NC5CCCCC5

Molecular Formula

C24H27N5O2

Molecular Weight

417.50

Precautions

P264-P270-P330-P501

References & Citations

[1]Huang H, et al. A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. Front Microbiol. 2017 Jun 7;8:1035.